IMRX — Immuneering Corp · catalysts, narrative & risks

Context (as of 2026-10-31)

Immuneering Corporation (Nasdaq: IMRX) is a late-stage clinical oncology company headquartered in Cambridge, Massachusetts, developing atebimetinib (IMM-1-104), an oral MEK/RAF inhibitor in a pivotal Phase 3 trial for pancreatic cancer, plus a lung-cancer combination program and discovery-stage programs [1], [7], [16]. As of late October the stock traded around $3.74, roughly 56% below its 52-week high of $8.48 [16], [17].

Key Recent Catalysts (July–October 2026)